Wave Life Sciences Ltd.
For the period ended Sep 30, 2025. Filed Nov 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 10, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
During the three months ended September 30, 2025, certain of our officers (as defined in Rule 16a-1(f) of the Exchange Act) and directors entered into contracts, instructions or written plans (each, a “Rule 10b5-1 Trading Plan” and collectively, the “Rule 10b5-1 Trading Plans”) for the purchase or sale of our securities that are intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information. We describe the material terms of these Rule 10b5-1 Trading Plans below.
On August 5, 2025, Christopher Francis, Ph.D., our Senior Vice President, Corporate Development, Head of Emerging Areas, adopted a Rule 10b5-1 Trading Plan providing for the sale of up to an aggregate of 520,702 of our ordinary shares pursuant to the terms of such Rule 10b5-1 Trading Plan. Dr. Francis’ Rule 10b5-1 Trading Plan is active until March 2, 2026, or earlier, if and when all transactions under the Rule 10b5-1 Trading Plan are completed.
On August 6, 2025, Mark Corrigan, M.D., a member of our board of directors, adopted a Rule 10b5-1 Trading Plan providing for the sale of up to an aggregate of 16,115 of our ordinary shares pursuant to the terms of such Rule 10b5-1 Trading Plan. Dr. Corrigan’s Rule 10b5-1 Trading Plan is active until March 31, 2026, or earlier, if and when all transactions under the Rule 10b5-1 Trading Plan are completed.
On August 6, 2025, Christian Henry, MBA, Chairman of our board of directors, adopted a Rule 10b5-1 Trading Plan providing for the sale of up to an aggregate of 93,445 of our ordinary shares pursuant to the terms of such Rule 10b5-1 Trading Plan. Mr. Henry’s Rule 10b5-1 Trading Plan is active until July 30, 2026, or earlier, if and when all transactions under the Rule 10b5-1 Trading Plan are completed.
On August 5, 2025, Adrian Rawcliffe, a member of our board of directors, adopted a Rule 10b5-1 Trading Plan providing for the sale of up to an aggregate of 58,115 ofour ordinary shares pursuant to the terms of such Rule 10b5-1 Trading Plan. Mr. Rawcliffe’s Rule
10b5-1 Trading Plan is active until August 16, 2026, or earlier, if and when all transactions under the Rule 10b5-1 Trading Plan are completed.
On August 6, 2025, Aik Na Tan, a member of our board of directors, adopted a Rule 10b5-1 Trading Plan providing for the sale of up to an aggregate of 135,345 of our ordinary shares pursuant to the terms of such Rule 10b5-1 Trading Plan. Ms. Tan’s Rule 10b5-1 Trading Plan is active until March 31, 2026, or earlier, if and when all transactions under the Rule 10b5-1 Trading Plan are completed.
Except as disclosed above, none of our directors or executive officers adopted, modified orterminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” as such term is defined in Item 408(a) of Regulation S-K, during the fiscal quarter ended September 30, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.